Epoch Investment Partners Inc. Has $84.40 Million Position in IDEXX Laboratories, Inc. $IDXX

Key Points

• Epoch Investment Partners Inc. increased its stake in IDEXX Laboratories by 17.4%, holding 200,967 shares valued at approximately $84.40 million as of the last reporting period.
• Analysts have shown bullish sentiment towards IDEXX Laboratories, upgrading its ratings, with price targets set as high as $675.00 by JPMorgan Chase & Co.
• IDEXX Laboratories reported a quarterly earnings per share (EPS) of $3.63, surpassing estimates by $0.35 and achieving a revenue growth of 10.6% year-over-year.

Epoch Investment Partners Inc. lifted its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 17.4% during the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 200,967 shares of the company's stock after purchasing an additional 29,796 shares during the period. Epoch Investment Partners Inc. owned 0.25% of IDEXX Laboratories worth $84,396,000 at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in the business. J. Stern & Co. LLP grew its holdings in shares of IDEXX Laboratories by 16.9% during the first quarter. J. Stern & Co. LLP now owns 4,655 shares of the company's stock worth $1,955,000 after purchasing an additional 672 shares during the last quarter. Caisse DE Depot ET Placement DU Quebec grew its holdings in shares of IDEXX Laboratories by 3.5% during the first quarter. Caisse DE Depot ET Placement DU Quebec now owns 167,974 shares of the company's stock worth $70,541,000 after purchasing an additional 5,664 shares during the last quarter. Comerica Bank boosted its holdings in IDEXX Laboratories by 1.7% in the first quarter. Comerica Bank now owns 16,738 shares of the company's stock valued at $7,029,000 after acquiring an additional 276 shares during the last quarter. Freedom Investment Management Inc. boosted its holdings in IDEXX Laboratories by 4.0% in the first quarter. Freedom Investment Management Inc. now owns 1,584 shares of the company's stock valued at $665,000 after acquiring an additional 61 shares during the last quarter. Finally, Southeast Asset Advisors LLC acquired a new stake in shares of IDEXX Laboratories during the first quarter worth about $422,000. Institutional investors own 87.84% of the company's stock.

Wall Street Analyst Weigh In

IDXX has been the subject of a number of analyst reports. Wall Street Zen upgraded IDEXX Laboratories from a "hold" rating to a "buy" rating in a research note on Saturday, July 12th. JPMorgan Chase & Co. raised their price target on IDEXX Laboratories from $550.00 to $675.00 and gave the company an "overweight" rating in a research note on Monday, August 4th. Leerink Partners raised their price target on IDEXX Laboratories from $580.00 to $600.00 and gave the company an "outperform" rating in a research note on Thursday, July 17th. Stifel Nicolaus set a $640.00 price target on IDEXX Laboratories in a research note on Monday, August 4th. Finally, Jefferies Financial Group initiated coverage on IDEXX Laboratories in a research note on Tuesday, July 1st. They issued a "buy" rating and a $625.00 price target for the company. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat.com, IDEXX Laboratories has an average rating of "Moderate Buy" and a consensus price target of $649.44.

Insiders Place Their Bets

In related news, EVP Sharon E. Underberg sold 5,450 shares of the business's stock in a transaction on Friday, August 8th. The stock was sold at an average price of $651.60, for a total value of $3,551,220.00. Following the completion of the sale, the executive vice president directly owned 6,156 shares in the company, valued at $4,011,249.60. The trade was a 46.96% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Michael G. Erickson sold 406 shares of the business's stock in a transaction on Tuesday, August 12th. The shares were sold at an average price of $649.96, for a total value of $263,883.76. Following the completion of the sale, the executive vice president owned 11,287 shares of the company's stock, valued at $7,336,098.52. This trade represents a 3.47% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 51,870 shares of company stock worth $32,877,757 over the last three months. 0.98% of the stock is currently owned by corporate insiders.

IDEXX Laboratories Stock Performance

Shares of NASDAQ IDXX opened at $641.35 on Tuesday. The company has a current ratio of 1.11, a quick ratio of 0.79 and a debt-to-equity ratio of 0.31. IDEXX Laboratories, Inc. has a 12 month low of $356.14 and a 12 month high of $688.12. The stock has a 50 day moving average of $572.19 and a 200-day moving average of $495.65. The company has a market capitalization of $51.31 billion, a P/E ratio of 53.40, a P/E/G ratio of 4.18 and a beta of 1.49.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last released its quarterly earnings results on Monday, August 4th. The company reported $3.63 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.28 by $0.35. The business had revenue of $1.11 billion during the quarter, compared to the consensus estimate of $1.06 billion. IDEXX Laboratories had a return on equity of 64.42% and a net margin of 24.41%.The firm's quarterly revenue was up 10.6% on a year-over-year basis. During the same period in the previous year, the company posted $2.44 EPS. IDEXX Laboratories has set its FY 2025 guidance at 12.400-12.760 EPS. As a group, equities research analysts predict that IDEXX Laboratories, Inc. will post 11.93 EPS for the current year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.